Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pricing Rare Disease Drugs Requires Care As Payers Increase Scrutiny

Executive Summary

Value questions are expected to be asked by payers and others as larger pharma companies enter the orphan drug space and more treatments debut targeting rare diseases.
Advertisement

Related Content

Collaboration Needed To Ensure Access To Orphan Drugs – Express Scripts Exec
Pharma Industry Pushes A Broadened Meaning For “Orphan”
Pharma Industry Pushes A Broadened Meaning For “Orphan”
NORD Says Orphan Drug Act Is Fine As Is, Wants To Work For Improvements Within System
Who's Afraid Of Big Pharma? Perhaps The Rare Disease Community
FDA Steps Into Makena Pricing Dispute In The Name Of "Access"
FDA Steps Into Makena Pricing Dispute In The Name Of "Access"

Topics

Advertisement
UsernamePublicRestriction

Register

PS053720

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel